Smoking cessation intervention: An evidence-based approach

Postgraduate Medicine

Volumn 122, Issue 2, 2010, Pages 74-82

  Laniado Laborín, Rafael ^a  

^a UNIVERSIDAD AUTÓNOMA DE BAJA CALIFORNIA   (Mexico)

Author keywords

Bupropion; Nicotine; Smoking cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; DOPAMINE; FLUOXETINE; MECAMYLAMINE; NALTREXONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINE VACCINE; NICOTINIC RECEPTOR ALPHA4BETA2; NORADRENALIN; PLACEBO; SELEGILINE; VARENICLINE; ANTIDEPRESSANT AGENT; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; AGITATION; APPLICATION SITE RASH; ARTICLE; BEHAVIOR CHANGE; BEHAVIOR THERAPY; CIGARETTE SMOKING; COMORBIDITY; COUGHING; DEPRESSION; DEVELOPING COUNTRY; DIZZINESS; DRUG DOSE COMPARISON; DRUG SAFETY; DYSPEPSIA; EVIDENCE BASED MEDICINE; GROUP THERAPY; HEADACHE; HEALTH HAZARD; HICCUP; HUMAN; INHIBITION KINETICS; INSOMNIA; JAW PAIN; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NAUSEA; NEUROTRANSMITTER UPTAKE; NICOTINE REPLACEMENT THERAPY; NONHUMAN; NOSE IRRITATION; PATIENT COUNSELING; PATIENT DECISION MAKING; PATIENT EDUCATION; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR UPREGULATION; RECOMMENDED DRUG DOSE; RHINORRHEA; SEIZURE; SELF HELP; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; SNEEZING; SUICIDAL IDEATION; SYSTEMATIC REVIEW (TOPIC); THROAT IRRITATION; TOBACCO DEPENDENCE; TREATMENT CONTRAINDICATION; WITHDRAWAL SYNDROME; XEROSTOMIA; DIRECTIVE COUNSELING; DRUG COMBINATION; HEALTH; METHODOLOGY; REVIEW; SMOKING;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR THERAPY; BENZAZEPINES; BUPROPION; DIRECTIVE COUNSELING; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; NICOTINE; NICOTINIC AGONISTS; QUINOXALINES; SMOKING; SMOKING CESSATION; WORLD HEALTH;

EID: 77950355852     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.03.2124     Document Type: Article

References (88)

1. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER Package. Geneva, Switzerland: World Health Organization; 2008.
2. Tonstad S. Cigarette smoking, smoking cessation, and diabetes. Diabetes Res Clin Pract. 2009;85(1):4-13.
3. World Health Organization. Tobacco facts. http://www.who.int/tobacco/mpower/tobacco_facts. Accessed December 11, 2009.
4. Laniado-Laborín R. Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21st century. Int J Environ Res Public Health. 2009;6(1):209-224.
5. American Lung Association Epidemiology and Statistics Unit Research and Program Services. June 2007. http://www.notontobacco.com/media/files/Trends%20in%20Tobacco%20Use.pdf. Accessed December 11, 2009.
6. Molgaard CA, Laniado-Laborín R, Elder JP, De Moor C. The social epidemiology of smoking during pregnancy among Mexican women. NY State J Med. 1989;89(1):15-18.
7. US Department of Health and Human Services. Women and Smoking: a report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2001.
8. Cook DG, Strachan DP. Health effects of passive smoking-10: Summary of effects of parental smoking on the respiratory health of children and implications for research. Thorax. 1999;54(4):357-366.
9. Röske K, Hannöver W, Thyrian JE, John U, Hannich HJ. Smoking cessation counselling for pregnant and postpartum women among midwives, gynaecologists and paedietricians in Germany. Int J Environ Res Public Health. 2009;6(1):96-107.
10. Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorac Soc. 2006;3(6):535-538.
11. Saetta M. Airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(5 pt 2):S17-S20.
12. Saetta M, Di Stefano A, Maestrelli P, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis. 1993;147(2):301-306.
13. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax. 2000;55(1):12-18.
14. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J. 2005;2(5)6:835-845.
15. Soriano JB, Agustí A. The yin and yang of COPD: or balancing repair (yang) and inflammation (yin). Eur Respir J. 2008;32(6):1426-1427.
16. The 2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 Update US Public Health Service Clinical Practice Guideline executive summary. Respir Care. 2008;53(9):1217-1222.
17. Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest. 2002;121(3):932-941.
18. Ranney L, Melvin C, Lux L, McClain E, Lohr KN. Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med. 2006;145(11):845-856.
19. Jiménez-Ruiz CA, Masa F, Miravitlles M, et al. Smoking characteristics: Differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest. 2001;119(5):1365-1370.
20. Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51(3):390-395.
21. Farkas AJ, Pierce JP, Zhu SH, et al. Addiction versus stages of change models in predicting smoking cessation. Addiction. 1996;91(9):1271-1280.
22. Okuyemi KS, Nolen NL, Ahluwalia JS. Interventions to facilitate smoking cessation. Am Fam Phys. 2006;74:262-271.
23. Hughes JR. Motivating and helping smokers to stop smoking. J Gen Intern Med. 2003;18(2):1053-1057.
24. Carrozi L, Pistelli F, Viegi G. Pharmacotherapy for smoking cessation. Ther Adv Respir Dis. 2008;2:301-317.
25. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;1:CD000031.
26. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA. 2000;283(24):3244-3254.
27. Waugh JB, Lorish ChD. New guideline on treating tobacco use and dependence: 2008 update is an opportunity to advance. Respir Care. 2008;53(9):1166-1168.
28. Schmelzle J, Rosser WW, Birtwhistle R. Update on pharmacologic and nonpharmacologic therapies for smoking cessation. Can Fam Physician. 2008;54(7):994-999.
29. US Department of Health and Human Services. Healthy people 2010. Washington, DC: US Department of Health and Human Services; 2000.
30. Wadland WC, Stoffelmayr B, Berger E, Crombach A, Ives K. Enhancing smoking cessation rates in primary care. J Fam Pract. 1999;48(9):711-718.
31. Katz DA, Muehlenbruch DR, Brown RB, Fiore MC, Baker TB; AHRQ Smoking Cessation Guideline Study Group. Effectiveness of a clinic-based strategy for implementing the AHRQ Smoking Cessation Guideline in primary care. Prev Med. 2002;35(3):293-301.
32. Gold PM. The 2007 GOLD Guidelines: a comprehensive care framework. Respir Care. 2009;54:1040-1049.
33. Hughes JR, Gulliver SB, Fenwick JW, et al. Smoking cessation among self-quitters. Health Psychol. 1992;11(5):331-334.
34. Morgan MD, Britton JR. Chronic obstructive pulmonary disease 8: non-pharmacological management of COPD. Thorax. 2003;58(5):453-457.
35. Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health. 2006;6:300.
36. Lancaster T, Stead LF. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2004;4:CD000165.
37. Britton J, Knox A. Helping people to stop smoking: the new smoking cessation guidelines. Thorax. 1999;54(1):1-2.
38. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD. Update 2009. http://www.goldcopd.org. Accessed December 11, 2009.
39. van Schayck CP, Kaper J. Smoking and COPD: will they ever vanish into smoke? Primary Care Respir J. 2006;15(2):81-83.
40. Stratelis G, Mölstad S, Jakobsson P, Zetterström O. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scand J Primary Health Care. 2006;24(3):133-139.
41. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008;1:CD000146.
42. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340(9):685-691.
43. Meine TJ, Patel MR, Washam JB, Pappas PA, Jollis JG. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol. 2005;95(8):976-978.
44. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335(24):1792-1798.
45. Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med. 2002;162(11):1267-1276.
46. Shiffman S, Dresler CM, Rohay JM. Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. Addiction. 2004;99(1):83-92.
47. Choi JH, Dresler CM, Norton MR, Strahs KR. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res. 2003;5(5):635-644.
48. McClure JB, Swan GE. Tailoring nicotine replacement therapy: rationale and potential approaches. CNS Drugs. 2006;20(4):281-291.
49. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ. 2009;338:b1024.
50. Aubin HJ. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs. 2002;62(suppl 2):45-52.
51. Hays JT, Ebbert JO. Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits. CNS Drugs. 2003;17(2):71-83.
52. Ferry L, Johnston JA. Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience. Int J Clin Pract. 2003;57(3):224-230.
53. Purvis TL, Mambourg SE, Balvanz TM, Magallon HE, Pham RH. Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness. Ann Pharmacother. 2009;43(5):862-867.
54. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48(10):3474-3477.
55. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract. 2006;60(5):571-576.
56. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ. 2008;179(8):135-144.
57. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166(15):1571-1577.
58. Jorenby DE, Hays JT, Rigotti NA, et al; Varenicline Phase 3 Study Group. Efficacy of varenicline, an G4b2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-63.
59. Tonstad S, Tønnensen P, Hajek P, Williams KE, Billing CB, Reeves KR; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64-71.
60. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha-4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo-and bupropion controlled trial with 1-year follow-up. Arch Intern Med. 2006;166(15):1561-1568.
61. Lyon GJ. Possible varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline personality disorder, and methamphetamine abuse in remission. J Clin Psychopharmacol. 2008;28(6):720-721.
62. Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf. 2009;32(2):119-135.
63. Gonzales D, Rennard SI, Nides M, et al; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55.
64. Pumariega AJ, Nelson R, Rotenberg L. Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr. 2008;13(6):511-514.
65. Food and Drug Administration. FDA Med Watch Alert, varenicline (marketed as Chantix) information, February 1, 2008 and November 20, 2007. www. fda.gov/cder/drug/infopage/varenicline/default.htm. Accessed December 11, 2009.
66. Lancaster T, Stead LF. Individual behavioral counselling for smoking cessation. Cochrane Database Syst Rev. 2005;2:CD001292.
67. Willemse B, Lesman-Leegte I, Timens W, Postma D, ten Hacken N. High cessation rates of cigarette smoking in subjects with and without COPD. Chest. 2005;128(5):3685-3687.
68. Lancaster T, Stead LF. Self-help interventions for smoking cessation. Cochrane Database Syst Rev. 2005;3:CD001118.
69. Stead LF, Perera R, Lancaster T. Telephone counseling for smoking cessation. Cochrane Database Syst Rev. 2006;3:CD002850.
70. Swartz LH, Noell JW, Schroeder SW, Ary DV. A randomised control study of a fully automated internet based smoking cessation programme. Tob Control. 2006;15(1):7-12.
71. Bader P, McDonald P, Selby P. An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts. Tobacco Control. 2009;18(1):34-42.
72. Steinberg MB, Greenhaus S, Schmelzer AC, et al. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med. 2009;150(7):447-454.
73. Etter JF. Internet-based smoking cessation programs. Int J Med Inform. 2006;75(1):110-116.
74. Molyneux A, Lewis S, Leivers U, et al. Clinical trial comparing nicotine replacement therapy (NRT) plus brief counseling, brief counseling alone, and minimal intervention on smoking cessation in hospital inpatients. Thorax. 2003;58(6):484-488.
75. Simon JA, Carmody TP, Hudes ES, Snyder E, Murray J. Intensive smoking cessation counselling versus minimal counselling among hospitalized smokers treated with transdermal nicotine replacement: a randomized trial. Am J Med. 2003;114(7):555-562.
76. Macleod ZR, Charles MA, Arnaldi VC, Adams IM. Telephone counseling as an adjunct to nicotine patches in smoking cessation: a randomized controlled trial. Med J Aust. 2003;179(7):349-352.
77. Halpin DM, Miravitlles M. Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc. 2006;3(7):619-623.
78. Siu EC, Tyndale RF. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Ther. 2008;324(3):992-999.
79. Schnoll RA, Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs. 2006;11(3):429-444.
80. Foulds J, Steinberg MB, Williams JM, Ziedonis DM. Developments in pharmacotherapy for tobacco dependence: past, present and future. Drug Alcohol Rev. 2006;25(1):59-71.
81. Maurer P, Jennings GT, Willers J, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity. Eur J Immunol. 2005;35(7):2031-2040.
82. Berrettini WH, Lerman CE. Pharmacotherapy and pharmacogenetics of nicotine dependence. Am J Psychiatry. 2005;162(8):1441-1451.
83. Pride NB. Smoking cessation: effects on symptoms, spirometry and future trends in COPD. Thorax. 2001;56(suppl 2):ii7-ii10.
84. Lindblom N, de Villiers SH, Kalayanov G, Gordon S, Johansson AM, Svensson TH. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration. 2002;69(3):254-260.
85. Pentel P, Malin D. A vaccine for nicotine dependence: targeting the drug rather than the brain. Respiration. 2002;69(3):193-197.
86. Vocci FJ, Chiang CN. Vaccines against nicotine: how effective are they likely to be in preventing smoking? CNS Drugs. 2001;15(7):505-514.
87. Hall WD. Will nicotine genetics and a nicotine vaccine prevent cigarette smoking and smoking-related diseases? PLoS Med. 2005;2(9):e266.
88. de Villiers SH, Lindblom N, Kalayanov G, et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration. 2002;69(3):247-253.